Document is current
Any future updates will be listed below
-
Authors
Xu, Haineng https://orcid.org/0000-0001-7195-4897
George, Erin
Gallo, David
Medvedev, Sergey
Wang, Xiaolei
Datta, Arindam
Kryczka, Rosie
Hyer, Marc L.
Fourtounis, Jimmy
Stocco, Rino
Aguado-Fraile, Elia
Petrone, Adam
Yin, Shou Yun
Shiwram, Ariya
Liu, Fang
Anderson, Matthew
Kim, Hyoung https://orcid.org/0000-0002-9975-8545
Greenberg, Roger A. https://orcid.org/0000-0003-1326-8981
Marshall, C. Gary
Simpkins, Fiona https://orcid.org/0000-0002-0840-2368
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R37CA215436-06, 5-P50-CA-228991-04, 1U54CA283759-01, 1 R50CA283807-01A1)
Foundation for Women's Cancer
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 14 March 2025
First Online: 1 April 2025
Competing interests
: F.S. serves on scientific advisory boards for AstraZeneca, GSK, and Zentalis Pharmaceuticals. She has received institutional research funding from AstraZeneca, Repare Therapeutics, Instill Bio, and Sierra Oncology. R.K., J.F., R.S., E.A., S.Y.Y., C.G.M. are, and D.G., M.L.H., A.P., A.S. were employees of Repare Therapeutics. R.A.G. serves on the scientific advisory board for Dong-A ST. All other authors declare no competing interests.
